FDA Approval Application for Dapagliflozin Submitted by Aizant
Aizant has submitted an original application (ANDA211523) for dapagliflozin, which is currently under standard review by the FDA.
Asset / Drug
Drug and asset intelligence for Aizant with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
SGLT2 Inhibitor
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.